Daaweynta CAR-T ee Neuroblastoma-ka Soo Noqnoqday/Ka-hortagga

Daaweynta GD2 CAR-Twaa daaweyn difaac oo cusub oo hidde ahaan wax ka beddesha unugyada T ee bukaanka si ay u aqoonsadaan una weeraraan unugyada neuroblastoma ee muujinaya antigen-ka GD2. Daaweyntan waxaa si gaar ah loogu talagalay bukaanada qaba neuroblastoma-ka halista sare leh ee soo noqnoqda ama aan firfircoonayn waxayna muujisay natiijooyin caafimaad oo rajo leh oo tijaabooyin ah.

• Xaaladda Cudurka: Cudurka neerfaha ee khatarta sare leh oo leh cudur joogto ah, soo noqnoqda, ama sii socda ka dib daaweynta safka hore.

• Qodobo Dheeraad ahCudurka faafa, kordhinta MYCN, ama iska caabbinta daaweynta dhaqameed.

Tallaabooyinka Muhiimka ah

1. Horudhac: Limfa oo joogsada ka hor inta aan la gelin.

2. Faleebo: Qiyaasta saxda ah ee unugyada GD2-CAR-T (lagu taliyay: 10×10^6 unugyada T ee CAR-positive/kg).

3. DabagalSawir-qaadis joogto ah (PET/CT, MRI) iyo qiimeyn dhuuxa lafta ka dib galinta.

Natiijooyinka Caafimaadka

• Heerka Jawaabta: 33% waxay gaareen cafis dhammaystiran (CR), iyadoo heerka jawaab celinta guud (CR+PR) uu yahay 63%.

• Badbaadada: 3 sano oo badbaado guud ah (OS) oo ah 60% iyo badbaadada aan dhacdooyinka lahayn (EFS) oo ah 36% qiyaasta lagu taliyay.

• Astaanta BadbaadadaDhacdooyinka ugu badan ee aan wanaagsanayn waxay ahaayeen kuwa la maarayn karo ee sii daynta cytokine ee heerka 1-2 (74%).

Faa'iidooyinkayaga

• GAAR-KA JIILKA 3-AAD: Domains-ka laba-geesoodka ah ee isku-darka ah (CD28 + 4-1BB) waxay kordhiyaan awoodda iyo adkeysiga unugyada T.

• Beddelka Badbaadada: Hidde-sidayaasha isku dhafan ee iC9 waxay u oggolaanayaan xakamaynta degdega ah ee sunta haddii loo baahdo.

• Rikoor la xaqiijiyayGuul laga gaaray tijaabooyinka caafimaad iyadoo la adeegsanayo xog dabagal dheer oo xooggan.